Omeros Phase 3 ARTEMIS-IGAN trial fails primary endpoint; narsoplimab BLA in IgAN discontinued

OMEROS CORP

Narsoplimab did not achieve statistically significant reduction in proteinuria at 36 weeks vs placebo (24-hour UPE >2 g/day).
Placebo group showed markedly greater proteinuria reduction than in other IgA nephropathy trials.
Company will not submit BLA for narsoplimab in IgAN and is discontinuing the ARTEMIS-IGAN trial.
Funds redirected to OMS906 (alternative pathway inhibitor) Phase 2/3 programs and narsoplimab BLA resubmission for HSCT-TMA.
Narsoplimab was generally well tolerated with no new safety concerns.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.